Cargando…

The Cost-Effectiveness of Vaccination of Older Adults with an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Other Available Quadrivalent Vaccines in Germany

Enhanced quadrivalent influenza vaccines that include an adjuvant (aQIV) or a high dose of antigen (QIV-HD), which stimulate a stronger immune response in older adults than the standard vaccine (QIVe), are now approved. The objective of this research is to compare available vaccines and determine th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kohli, Michele A., Maschio, Michael, Cartier, Shannon, Mould-Quevedo, Joaquin, Fricke, Frank-Ulrich
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9503029/ https://www.ncbi.nlm.nih.gov/pubmed/36146464 http://dx.doi.org/10.3390/vaccines10091386

Ejemplares similares

The cost-effectiveness of an adjuvanted quadrivalent influenza vaccine in the United Kingdom
por: Kohli, Michele A., et al.
Publicado: (2021)

Cost-Effectiveness of Vaccination of Older Adults with an MF59(®)-Adjuvanted Quadrivalent Influenza Vaccine Compared to Standard-Dose and High-Dose Vaccines in Denmark, Norway, and Sweden
por: Jacob, Jorge, et al.
Publicado: (2023)

Immunogenicity and Safety of MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared with a Nonadjuvanted, Quadrivalent Influenza Vaccine in Adults 50–64 Years of Age
por: Poder, Airi, et al.
Publicado: (2023)

Cost-Effectiveness of the Use of Adjuvanted Quadrivalent Seasonal Influenza Vaccine in Older Adults in Ireland
por: Nguyen, Van Hung, et al.
Publicado: (2023)

Enhanced passive safety surveillance of the MF59-adjuvanted quadrivalent influenza vaccine in the elderly during the 2021/22 influenza season
por: Amicizia, Daniela, et al.
Publicado: (2023)

Vaccine Effectiveness of Cell-Based Quadrivalent Influenza Vaccine in Children: A Narrative Review
por: Mould-Quevedo, Joaquin F., et al.
Publicado: (2023)

An Economic Comparison in the Elderly of Adjuvanted Quadrivalent Influenza Vaccine with Recombinant Quadrivalent Influenza Vaccine in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2023)

Cost-Effectiveness Analysis of Switching from Trivalent to Quadrivalent Seasonal Influenza Vaccine in Argentina
por: Urueña, Analia, et al.
Publicado: (2021)

Clinical and Economic Outcomes Associated with Cell-Based Quadrivalent Influenza Vaccine vs. Standard-Dose Egg-Based Quadrivalent Influenza Vaccines during the 2018–19 Influenza Season in the United States
por: Krishnarajah, Girishanthy, et al.
Publicado: (2021)

A Real-World Clinical and Economic Analysis of Cell-Derived Quadrivalent Influenza Vaccine Compared to Standard Egg-Derived Quadrivalent Influenza Vaccines During the 2019–2020 Influenza Season in the United States
por: Divino, Victoria, et al.
Publicado: (2021)

An Economic Evaluation of the Adjuvanted Quadrivalent Influenza Vaccine Compared with Standard-Dose Quadrivalent Influenza Vaccine in the Spanish Older Adult Population
por: Fochesato, Anna, et al.
Publicado: (2022)

The rationale for quadrivalent influenza vaccines
por: Ambrose, Christopher S., et al.
Publicado: (2012)

Effectiveness of the MF59‐adjuvanted trivalent or quadrivalent seasonal influenza vaccine among adults 65 years of age or older, a systematic review and meta‐analysis
por: Coleman, Brenda L., et al.
Publicado: (2021)

Cost-Effectiveness and Burden of Disease for Adjuvanted Quadrivalent Influenza Vaccines Compared to High-Dose Quadrivalent Influenza Vaccines in Elderly Patients in Spain
por: Ruiz-Aragón, Jesús, et al.
Publicado: (2022)

The Epidemiological and Economic Impact of a Cell-Based Quadrivalent Influenza Vaccine in Adults in the US: A Dynamic Modeling Approach
por: Nguyen, Van Hung, et al.
Publicado: (2021)

Cost-effectiveness for high dose quadrivalent versus the adjuvanted quadrivalent influenza vaccine in the Italian older adult population
por: Rumi, Filippo, et al.
Publicado: (2023)

AS03- and MF59-Adjuvanted Influenza Vaccines in Children
por: Wilkins, Amanda L., et al.
Publicado: (2017)

Safety of MF59-Adjuvanted Influenza Vaccination in the Elderly: Results of a Comparative Study of MF59-Adjuvanted Vaccine Versus Nonadjuvanted Influenza Vaccine in Northern Italy
por: Villa, Marco, et al.
Publicado: (2013)

No safety signals for GSK quadrivalent influenza vaccine
Publicado: (2022)

Fluad®-MF59®-Adjuvanted Influenza Vaccine in Older Adults
por: Tsai, Theodore F
Publicado: (2013)

MF59(®)‐adjuvanted vaccines for seasonal and pandemic influenza prophylaxis
por: Banzhoff, Angelika, et al.
Publicado: (2008)

Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial
por: Esposito, Susanna, et al.
Publicado: (2020)

Cost–effectiveness analysis of quadrivalent influenza vaccine in Spain
por: García, Amos, et al.
Publicado: (2016)

Quadrivalent influenza nanoparticle vaccines induce broad protection
por: Boyoglu-Barnum, Seyhan, et al.
Publicado: (2021)

Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

The New Quadrivalent Adjuvanted Influenza Vaccine for the Italian Elderly: A Health Technology Assessment
por: Calabrò, Giovanna Elisa, et al.
Publicado: (2022)

Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Modelling the Economic Impact of lnfluenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada
por: Nguyen, Van Hung, et al.
Publicado: (2022)

Immunogenicity and safety of Quadrivalent Influenza HA vaccine compared with Trivalent Influenza HA vaccine and evaluation of Quadrivalent Influenza HA vaccine batch-to-batch consistency in Indonesian children and adults
por: Fadlyana, Eddy, et al.
Publicado: (2023)

1168. Cost-effectiveness of high-dose quadrivalent influenza vaccine versus standard-dose quadrivalent influenza vaccine for older people in a country with high influenza vaccination rate
por: Nham, Eliel, et al.
Publicado: (2023)

Memory-like innate response to booster vaccination with MF-59 adjuvanted influenza vaccine in children
por: Kazmin, Dmitri, et al.
Publicado: (2023)

Relative Effectiveness of the Cell-Cultured Quadrivalent Influenza Vaccine Compared to Standard, Egg-derived Quadrivalent Influenza Vaccines in Preventing Influenza-like Illness in 2017–2018
por: Boikos, Constantina, et al.
Publicado: (2020)

Correction to: Cell-Based Quadrivalent Inactivated Influenza Virus Vaccine (Flucelvax(®) Tetra/Flucelvax Quadrivalent(®)): A Review in the Prevention of Influenza
por: Lamb, Yvette N.
Publicado: (2019)

Will a Quadrivalent Vaccine Solve the Problem of Influenza B Mismatches?
por: Choi, Eun Hwa, et al.
Publicado: (2018)

Cost-effectiveness analysis of quadrivalent seasonal influenza vaccines in England
por: Thorrington, Dominic, et al.
Publicado: (2017)

Cost effectiveness of quadrivalent influenza vaccines in the elderly population of Malaysia
por: Aljunid, Syed Mohamed, et al.
Publicado: (2023)

Cost-effectiveness of vaccination with a quadrivalent HPV vaccine in Germany using a dynamic transmission model
por: Schobert, Deniz, et al.
Publicado: (2012)

Review of seasonal influenza in Canada: Burden of disease and the cost-effectiveness of quadrivalent inactivated influenza vaccines
por: Thommes, Edward W., et al.
Publicado: (2016)

Safety and immunogenicity of quadrivalent meningococcal polysaccharide vaccine (MPV ACYW135) compared with quadrivalent meningococcal conjugate vaccine (Menactra®) in Malian children
por: Sow, Samba O., et al.
Publicado: (2023)

Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden
por: Tisa, V., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_o83ldhklga05ehbnqv7nnv24c3